Hologic (NASDAQ:HOLX) Issues Earnings Results, Meets Estimates

by · The Cerbat Gem

Hologic (NASDAQ:HOLX – Get Free Report) released its quarterly earnings data on Monday. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01, Briefing.com reports. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 EPS.

Hologic Trading Down 5.9 %

Shares of NASDAQ:HOLX opened at $78.80 on Wednesday. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic has a 1 year low of $66.93 and a 1 year high of $84.67. The firm has a fifty day moving average price of $81.05 and a 200 day moving average price of $78.11. The stock has a market capitalization of $18.30 billion, a PE ratio of 26.80, a P/E/G ratio of 2.98 and a beta of 0.98.

Analyst Ratings Changes

A number of research firms have recently weighed in on HOLX. Leerink Partners dropped their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. JPMorgan Chase & Co. upped their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James upped their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Finally, UBS Group upped their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.25.

View Our Latest Analysis on Hologic

Hologic Company Profile

(Get Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Further Reading